Pregnane X Receptor(PXR) and Constitutive Androstane Receptor(CAR) in the Multidrug Resistance
10.11904/j.issn.1002-3070.2014.04.019
- VernacularTitle:孕烷X受体和组成型雄甾烷受体在肿瘤多药耐药中的研究进展
- Author:
Yan WANG
;
Guangmei ZHANG
- Publication Type:Journal Article
- Keywords:
Cancer;
Multidrug resistance;
PXR;
CAR
- From:
Practical Oncology Journal
2014;(4):377-381
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy is one of the three most common treatment modalities for cancer .However , chemotherapy as current firstline therapy induces significant side effects and limited efficacy ,leading to multidrug resistance and fast recurrence challenging the patient survival rate .Drug metabolizing enzymes ( DMEs) and efflux transporters promote the metabolism,clearance,and detoxification of chemotherapeutic agents .Nuclear receptors, especially pregnane X receptor (PXR,NR112)and constitutive androstane activated receptor (CAR,NR113),reg-ulate the expressions of target genes that could encode phase I DMEs ,phase II DMEs,and efflux transporters in the development of multidrug resistance ( MDR) during chemotherapy .Recent studies have revealed that PXR and CAR play pivotal roles in MDR of various human carcinomas .And their expressve levels or activation statuses could predict the risk of drug resistance in the patients subjected to chemotherapy .Accordingly ,PXR/CAR antag-onists,combining with existing chemotherapeutics that activate PXR /CAR,are promising options that could over-come MDR in cancer.
